BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Fujiwara N, Friedman SL, Goossens N, Hoshida Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J Hepatol 2018;68:526-49. [PMID: 28989095 DOI: 10.1016/j.jhep.2017.09.016] [Cited by in Crossref: 198] [Cited by in F6Publishing: 196] [Article Influence: 39.6] [Reference Citation Analysis]
Number Citing Articles
1 Lv L, Wang X, Ma T. microRNA-944 inhibits the malignancy of hepatocellular carcinoma by directly targeting IGF-1R and deactivating the PI3K/Akt signaling pathway. Cancer Manag Res 2019;11:2531-43. [PMID: 31114322 DOI: 10.2147/CMAR.S199818] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Ngo MT, Jeng HY, Kuo YC, Diony Nanda J, Brahmadhi A, Ling TY, Chang TS, Huang YH. The Role of IGF/IGF-1R Signaling in Hepatocellular Carcinomas: Stemness-Related Properties and Drug Resistance. Int J Mol Sci 2021;22:1931. [PMID: 33669204 DOI: 10.3390/ijms22041931] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Li Y, Lin N, Xu J, Lu Y, Chen S, Pan C, Wang C, Xu M, Zhou B, Xu R, Xu YJ. Measurement of Serum and Hepatic Eicosanoids by Liquid Chromatography Tandem-Mass Spectrometry (LC-MS/MS) in a Mouse Model of Hepatocellular Carcinoma (HCC) with Delivery of c-Met and Activated β-Catenin by Hepatocyte Hydrodynamic Injection. Med Sci Monit 2018;24:1670-9. [PMID: 29560932 DOI: 10.12659/msm.908931] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
4 . Therapie des HCC – Endlich Fortschritte. Z Gastroenterol 2021;59:496-7. [PMID: 34224132 DOI: 10.1055/a-1402-4960] [Reference Citation Analysis]
5 Çolaklar A, Altınbaş NK. Infiltrative non-mass-like hepatocellular carcinoma initially presenting with isolated malignant portal vein thrombosis: A case report and review of the literature. J Ultrason 2020;20:e55-60. [PMID: 32320167 DOI: 10.15557/JoU.2020.0009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Yuan Y, Che L, Qi C, Meng Z. Protective effects of polysaccharides on hepatic injury: A review. Int J Biol Macromol 2019;141:822-30. [PMID: 31487518 DOI: 10.1016/j.ijbiomac.2019.09.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
7 Zhang G, Fan W, Wang H, Wen J, Tan J, Xue M, Li J. Non-Apoptotic Programmed Cell Death-Related Gene Signature Correlates With Stemness and Immune Status and Predicts the Responsiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:844013. [DOI: 10.3389/fcell.2022.844013] [Reference Citation Analysis]
8 Zhang Y, Shu Z, Ye Q, Chen J, Zhong J, Jiang H, Wu C, Yu T, Pang P, Ma T, Lin C. Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma via Multi-Parametric MRI Radiomics. Front Oncol 2021;11:633596. [PMID: 33747956 DOI: 10.3389/fonc.2021.633596] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Su ZL, Su CW, Huang YL, Yang WY, Sampurna BP, Ouchi T, Lee KL, Wu CS, Wang HD, Yuh CH. A Novel AURKA Mutant-Induced Early-Onset Severe Hepatocarcinogenesis Greater than Wild-Type via Activating Different Pathways in Zebrafish. Cancers (Basel) 2019;11:E927. [PMID: 31269749 DOI: 10.3390/cancers11070927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
10 Tsilimigras DI, Mehta R, Moris D, Sahara K, Bagante F, Paredes AZ, Farooq A, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Utilizing Machine Learning for Pre- and Postoperative Assessment of Patients Undergoing Resection for BCLC-0, A and B Hepatocellular Carcinoma: Implications for Resection Beyond the BCLC Guidelines. Ann Surg Oncol 2020;27:866-74. [DOI: 10.1245/s10434-019-08025-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
11 Ning G, Li Y, Chen W, Tang W, Shou D, Luo Q, Chen H, Zhou Y. Identification of New Biomarker for Prediction of Hepatocellular Carcinoma Development in Early-Stage Cirrhosis Patients. J Oncol 2021;2021:9949492. [PMID: 34335764 DOI: 10.1155/2021/9949492] [Reference Citation Analysis]
12 Wang Z, Rehman AU, Qin X, Zhu C, Wu S, Bukhari I. PI3K/AKT/mTOR Pathway-Associated Genes Reveal a Putative Prognostic Signature Correlated with Immune Infiltration in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-18. [DOI: 10.1155/2022/7545666] [Reference Citation Analysis]
13 Ren Y, Wang Y, Hao S, Yang Y, Xiong W, Qiu L, Tao J, Tang A. NFE2L3 promotes malignant behavior and EMT of human hepatocellular carcinoma (HepG2) cells via Wnt/β‑catenin pathway. J Cancer 2020;11:6939-49. [PMID: 33123284 DOI: 10.7150/jca.48100] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Ferreira GD, Fernandes GMM, Penteado C, Cória VR, Galbiatti-Dias ALDS, Russo A, Castanhole-Nunes MMU, Silva RFD, Silva RCMAD, Pavarino ÉC, Torreglosa Ruiz Cintra M, Goloni-Bertollo EM. Polymorphisms in xenobiotic metabolism-related genes in patients with hepatocellular carcinoma: a case-control study. Xenobiotica 2021;51:737-44. [PMID: 33896378 DOI: 10.1080/00498254.2021.1893408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hester CA, Yopp AC. Surgical Therapies in Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 145-67. [DOI: 10.1007/978-3-030-21540-8_8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Simon TG, Chan AT. Lifestyle and Environmental Approaches for the Primary Prevention of Hepatocellular Carcinoma. Clin Liver Dis 2020;24:549-76. [PMID: 33012445 DOI: 10.1016/j.cld.2020.06.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zeng X, Tan C, Mo M, Qin X, Ma X, Huang K, Wang X, Liang W, Yang L. CircRNA profiling identifies circRNF180 as a tumor suppressor in hepatocellular carcinoma. Epigenomics 2021;13:513-30. [PMID: 33683141 DOI: 10.2217/epi-2020-0385] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Tsilimigras DI, Hyer JM, Diaz A, Moris D, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Impact of time-to-surgery on outcomes of patients undergoing curative-intent liver resection for BCLC-0, A and B hepatocellular carcinoma. J Surg Oncol 2021;123:381-8. [PMID: 33174627 DOI: 10.1002/jso.26297] [Reference Citation Analysis]
19 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
20 Fan X, Huang X, Hershman M, Zheng X, Jiang C, Yue B, Weisberg I. Portal vein thrombosis prevalence and mortality among alcoholic cirrhosis in a nationwide inpatient cohort. Eur J Gastroenterol Hepatol 2020;32:1160-7. [PMID: 31834054 DOI: 10.1097/MEG.0000000000001624] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Arechederra M, Recalde M, Gárate-Rascón M, Fernández-Barrena MG, Ávila MA, Berasain C. Epigenetic Biomarkers for the Diagnosis and Treatment of Liver Disease. Cancers (Basel) 2021;13:1265. [PMID: 33809263 DOI: 10.3390/cancers13061265] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Hsu YC, Suri V, Nguyen MH, Huang YT, Chen CY, Chang IW, Tseng CH, Wu CY, Lin JT, Pan DZ, Gaggar A, Podlaha O. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation. Gastroenterology 2022;162:1160-1170.e1. [PMID: 34995536 DOI: 10.1053/j.gastro.2021.12.286] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
23 Fujiwara N, Fobar AJ, Raman I, Li QZ, Marrero JA, Parikh ND, Singal AG, Hoshida Y. A Blood-Based Prognostic Liver Secretome Signature Predicts Long-term Risk of Hepatic Decompensation in Cirrhosis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00329-3. [PMID: 33727162 DOI: 10.1016/j.cgh.2021.03.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
24 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Reference Citation Analysis]
25 Moeini A, Torrecilla S, Tovar V, Montironi C, Andreu-Oller C, Peix J, Higuera M, Pfister D, Ramadori P, Pinyol R, Solé M, Heikenwälder M, Friedman SL, Sia D, Llovet JM. An Immune Gene Expression Signature Associated With Development of Human Hepatocellular Carcinoma Identifies Mice That Respond to Chemopreventive Agents. Gastroenterology 2019;157:1383-1397.e11. [PMID: 31344396 DOI: 10.1053/j.gastro.2019.07.028] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
26 Liu J, Xia L, Wang S, Cai X, Wu X, Zou C, Shan B, Luo M, Wang D. E2F4 Promotes the Proliferation of Hepatocellular Carcinoma Cells through Upregulation of CDCA3. J Cancer 2021;12:5173-80. [PMID: 34335934 DOI: 10.7150/jca.53708] [Reference Citation Analysis]
27 Anyasor GN, Idowu DP, Nabofa W. Evaluation of the hepatoprotective effect of oral administration of aqueous fraction of methanolic extract of Costus afer leaves during induction of hepatocellular carcinoma with diethylnitrosamine in rats. Comp Clin Pathol 2020;29:733-44. [DOI: 10.1007/s00580-020-03124-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Hu S, Lyu X, Li W, Cui X, Liu Q, Xu X, Wang J, Chen L, Zhang X, Yin Y, Teekaraman Y. Radiomics Analysis on Noncontrast CT for Distinguishing Hepatic Hemangioma (HH) and Hepatocellular Carcinoma (HCC). Contrast Media & Molecular Imaging 2022;2022:1-8. [DOI: 10.1155/2022/7693631] [Reference Citation Analysis]
29 Wang P, Yan Y, Yu W, Zhang H. Role of ten-eleven translocation proteins and 5-hydroxymethylcytosine in hepatocellular carcinoma.Cell Prolif. 2019;52:e12626. [PMID: 31033072 DOI: 10.1111/cpr.12626] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
30 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
31 Chan LK, Tsui YM, Ho DW, Ng IO. Cellular heterogeneity and plasticity in liver cancer. Semin Cancer Biol 2021:S1044-579X(21)00050-X. [PMID: 33647386 DOI: 10.1016/j.semcancer.2021.02.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Lee T, Rawding PA, Bu J, Hyun S, Rou W, Jeon H, Kim S, Lee B, Kubiatowicz LJ, Kim D, Hong S, Eun H. Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14:2061. [PMID: 35565192 DOI: 10.3390/cancers14092061] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
33 Li J, Wu DB, Jiang W, Chen XB, Xiao GB, Wang YH, Wang ML, Tao YC, Chen EQ. Efficacy and safety of sofosbuvir-based pangenotypic direct-acting antiviral agents for chronic hepatitis C patients without genotype determination: Real-world experience of a retrospective study. Medicine (Baltimore) 2020;99:e22726. [PMID: 33120769 DOI: 10.1097/MD.0000000000022726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Tsilimigras DI, Mehta R, Guglielmi A, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: A novel tumor-burden based prediction model. J Surg Oncol 2020;122:955-63. [PMID: 32602143 DOI: 10.1002/jso.26091] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
35 Khajeh E, Moghadam AD, Eslami P, Ali-hasan-al-saegh S, Ramouz A, Shafiei S, Ghamarnejad O, Dezfouli SA, Rupp C, Springfeld C, Carvalho C, Probst P, Mousavizadeh SM, Mehrabi A. Statin use is associated with the reduction in hepatocellular carcinoma recurrence after liver surgery. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09192-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Dai Y, Qiang W, Lin K, Gui Y, Lan X, Wang D. An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma. Cancer Immunol Immunother 2021;70:967-79. [PMID: 33089373 DOI: 10.1007/s00262-020-02743-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
37 Li J, Xu J, Li Z. Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade. Transl Oncol 2021;14:101116. [PMID: 33975180 DOI: 10.1016/j.tranon.2021.101116] [Reference Citation Analysis]
38 Ge JC, Wang YX, Chen ZB, Chen DF. Integrin alpha 7 correlates with poor clinical outcomes, and it regulates cell proliferation, apoptosis and stemness via PTK2-PI3K-Akt signaling pathway in hepatocellular carcinoma. Cell Signal 2020;66:109465. [PMID: 31698037 DOI: 10.1016/j.cellsig.2019.109465] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
39 Zhang C, Wang P, Li Y, Huang C, Ni W, Chen Y, Shi J, Chen G, Hu X, Ye M, Duan S, Wang K. Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Anat Rec (Hoboken) 2019;302:193-200. [PMID: 30312023 DOI: 10.1002/ar.23954] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
40 Jang H, Yoon JS, Park SY, Lee HA, Jang MJ, Kim SU, Sinn DH, Seo YS, Kim HY, Kim SE, Jun DW, Yoon EL, Sohn JH, Ahn SB, Shim JJ, Jeong SW, Cho YK, Kim HS, Nam JY, Lee YB, Kim YJ, Yoon JH, Zoulim F, Lampertico P, Dalekos GN, Idilman R, Sypsa V, Berg T, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Janssen H, Papatheodoridis GV, Lee JH. Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients With Chronic Hepatitis B. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00935-6. [PMID: 34500103 DOI: 10.1016/j.cgh.2021.09.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Chianese A, Santella B, Ambrosino A, Stelitano D, Rinaldi L, Galdiero M, Zannella C, Franci G. Oncolytic Viruses in Combination Therapeutic Approaches with Epigenetic Modulators: Past, Present, and Future Perspectives. Cancers (Basel) 2021;13:2761. [PMID: 34199429 DOI: 10.3390/cancers13112761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Li FY, Li JG, Wu SS, Ye HL, He XQ, Zeng QJ, Zheng RQ, An C, Li K. An Optimal Ablative Margin of Small Single Hepatocellular Carcinoma Treated with Image-Guided Percutaneous Thermal Ablation and Local Recurrence Prediction Base on the Ablative Margin: A Multicenter Study. J Hepatocell Carcinoma 2021;8:1375-88. [PMID: 34815974 DOI: 10.2147/JHC.S330746] [Reference Citation Analysis]
43 Isfordink CJ, Maan R, de Man RA, van Erpecum KJ, van der Meer AJ. Should we continue surveillance for hepatocellular carcinoma and gastroesophageal varices in patients with cirrhosis and cured HCV infection? Eur J Intern Med 2021:S0953-6205(21)00296-X. [PMID: 34563447 DOI: 10.1016/j.ejim.2021.08.023] [Reference Citation Analysis]
44 Nascimbeni F, Pellegrini E, Lugari S, Mondelli A, Bursi S, Onfiani G, Carubbi F, Lonardo A. Statins and nonalcoholic fatty liver disease in the era of precision medicine: More friends than foes. Atherosclerosis 2019;284:66-74. [DOI: 10.1016/j.atherosclerosis.2019.02.028] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 10.0] [Reference Citation Analysis]
45 Imamura T, Okamura Y, Ohshima K, Uesaka K, Sugiura T, Ito T, Yamamoto Y, Ashida R, Ohgi K, Otsuka S, Ohnami S, Nagashima T, Hatakeyama K, Kakuda Y, Sugino T, Urakami K, Akiyama Y, Yamaguchi K. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation. Cancer Med 2022. [PMID: 35174643 DOI: 10.1002/cam4.4571] [Reference Citation Analysis]
46 Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, Kudo M. Baseline Liver Function and Subsequent Outcomes in the Phase 3 REFLECT Study of Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:510-21. [PMID: 34721512 DOI: 10.1159/000516490] [Reference Citation Analysis]
47 Deepak P, Siddalingam R, Kumar P, Anand S, Thakur S, Jagdish B, Jaiswal S. Gene based nanocarrier delivery for the treatment of hepatocellular carcinoma. Journal of Drug Delivery Science and Technology 2020;59:101837. [DOI: 10.1016/j.jddst.2020.101837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 Zheng W, Yang J, Dong Z, Wang L, Fang M, Wu W, Yao D, Yao M. High mobility group box 3 as an emerging biomarker in diagnosis and prognosis of hepatocellular carcinoma. Cancer Manag Res. 2018;10:5979-5989. [PMID: 30538547 DOI: 10.2147/cmar.s181742] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
49 Simoes Eugénio M, Farooq M, Dion S, Devisme C, Raguenes-Nicol C, Piquet-Pellorce C, Samson M, Dimanche-Boitrel MT, Le Seyec J. Hepatocellular Carcinoma Emergence in Diabetic Mice with Non-Alcoholic Steatohepatitis Depends on Diet and Is Delayed in Liver Exhibiting an Active Immune Response. Cancers (Basel) 2020;12:E1491. [PMID: 32521615 DOI: 10.3390/cancers12061491] [Reference Citation Analysis]
50 Nakano M, Yatsuhashi H, Bekki S, Takami Y, Tanaka Y, Yoshimaru Y, Honda K, Komorizono Y, Harada M, Shibata M, Sakisaka S, Shakado S, Nagata K, Yoshizumi T, Itoh S, Sohda T, Oeda S, Nakao K, Sasaki R, Yamashita T, Ido A, Mawatari S, Nakamuta M, Aratake Y, Matsumoto S, Maeshiro T, Goto T, Torimura T. Trends in hepatocellular carcinoma incident cases in Japan between 1996 and 2019. Sci Rep 2022;12:1517. [PMID: 35087153 DOI: 10.1038/s41598-022-05444-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Chen Q, Ayer T, Adee MG, Wang X, Kanwal F, Chhatwal J. Assessment of Incidence of and Surveillance Burden for Hepatocellular Carcinoma Among Patients With Hepatitis C in the Era of Direct-Acting Antiviral Agents. JAMA Netw Open. 2020;3:e2021173. [PMID: 33206188 DOI: 10.1001/jamanetworkopen.2020.21173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Kawaguchi T, Inokuchi T, Honma T, Itano S, Kawasaki E, Inada C, Aoki T, Tsumura N, Araki A, Mukae T, Torimura T. Factors associated with advanced hepatic fibrosis in patients with various internal diseases: A multicenter community-based survey: Hypertension relates to hepatic fibrosis. Hepatol Res 2018;48:882-92. [DOI: 10.1111/hepr.13190] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
53 Li X, Wu Y, Suo P, Liu G, Li L, Zhang X, Chen S, Xu M, Song L. Identification of a novel germline frameshift mutation p.D300fs of PMS1 in a patient with hepatocellular carcinoma: A case report and literature review. Medicine (Baltimore) 2020;99:e19076. [PMID: 32000458 DOI: 10.1097/MD.0000000000019076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
54 Wu M, Yang S, Feng X, Li C, Liu X, Zhang Z, Xiao Y, Liu C, Dong J. Combining Preoperative and Postoperative Inflammatory Indicators Can Better Predict the Recurrence of Hepatocellular Carcinoma After Partial Hepatectomy. J Inflamm Res 2021;14:3231-45. [PMID: 34285546 DOI: 10.2147/JIR.S316177] [Reference Citation Analysis]
55 Zhang R, Xu L, Wen X, Zhang J, Yang P, Zhang L, Xue X, Wang X, Huang Q, Guo C, Shi Y, Niu T, Chen F. A nomogram based on bi-regional radiomics features from multimodal magnetic resonance imaging for preoperative prediction of microvascular invasion in hepatocellular carcinoma.Quant Imaging Med Surg. 2019;9:1503-1515. [PMID: 31667137 DOI: 10.21037/qims.2019.09.07] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 5.7] [Reference Citation Analysis]
56 Li J, Zhou Q, Rong L, Rong D, Yang Y, Hao J, Zhang Z, Ma L, Rao G, Zhou Y, Xiao F, Li C, Wang H, Li YP. Development of cell culture infectious clones for hepatitis C virus genotype 1b and transcription analysis of 1b-infected hepatoma cells. Antiviral Res 2021;193:105136. [PMID: 34252495 DOI: 10.1016/j.antiviral.2021.105136] [Reference Citation Analysis]
57 Sha M, Cao J, Zong ZP, Xu N, Zhang JJ, Tong Y, Xia Q. Identification of genes predicting unfavorable prognosis in hepatitis B virus-associated hepatocellular carcinoma. Ann Transl Med 2021;9:975. [PMID: 34277775 DOI: 10.21037/atm-21-2085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Abe T, Yamada D, Asukai K, Hasegawa S, Tomokuni A, Wada H, Fujii W, Ikezawa K, Fukutake N, Ohkawa K, Shinno N, Hara H, Yanagimoto Y, Takahashi Y, Sugimura K, Yamamoto K, Ushigome H, Haraguchi N, Nishimura J, Yasui M, Omori T, Miyata H, Ohue M, Yano M, Sakon M, Takahashi H. Decreased CT-number in the pancreatic parenchyma is a reliable imaging biomarker of the presence of malignancies in patients with high-risk intraductal papillary mucinous neoplasm. Pancreatology 2020;20:442-7. [PMID: 32146046 DOI: 10.1016/j.pan.2020.02.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
59 Kim DH, Choi SH, Shim JH, Kim SY, Lee SS, Byun JH, Choi JI. Meta-Analysis of the Accuracy of Abbreviated Magnetic Resonance Imaging for Hepatocellular Carcinoma Surveillance: Non-Contrast versus Hepatobiliary Phase-Abbreviated Magnetic Resonance Imaging. Cancers (Basel) 2021;13:2975. [PMID: 34198589 DOI: 10.3390/cancers13122975] [Reference Citation Analysis]
60 Da Fonseca LG, Forner A. Editorial: aspirin and NSAID for chemoprevention of hepatocellular carcinoma-ready for their use? Aliment Pharmacol Ther 2021;54:850-1. [PMID: 34425013 DOI: 10.1111/apt.16556] [Reference Citation Analysis]
61 Su L, Zhang G, Kong X. Prognostic Significance of Pregnancy Zone Protein and Its Correlation with Immune Infiltrates in Hepatocellular Carcinoma. Cancer Manag Res 2020;12:9883-91. [PMID: 33116846 DOI: 10.2147/CMAR.S269215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
62 Wegermann K, Hyun J, Diehl AM. Molecular Mechanisms Linking Nonalcoholic Steatohepatitis to Cancer. Clin Liver Dis (Hoboken) 2021;17:6-10. [PMID: 33552478 DOI: 10.1002/cld.1006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Fujiwara N, Hoshida Y. Hepatocellular Carcinoma Risk Stratification by Genetic Profiling in Patients with Cirrhosis. Semin Liver Dis 2019;39:153-62. [PMID: 30912093 DOI: 10.1055/s-0039-1681031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
64 Zhao J, Li H, Zhao S, Wang E, Zhu J, Feng D, Zhu Y, Dou W, Fan Q, Hu J, Jia L, Liu L. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling. Mol Cancer 2021;20:46. [PMID: 33658044 DOI: 10.1186/s12943-021-01343-5] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
65 Lonardo A, Ballestri S. Perspectives of nonalcoholic fatty liver disease research: a personal point of view. Exploration of Medicine 2020;1:85-107. [DOI: 10.37349/emed.2020.00007] [Cited by in Crossref: 9] [Article Influence: 4.5] [Reference Citation Analysis]
66 Seo HY, Lee SH, Lee JH, Lee JH, Jang BK, Kim MK. Kahweol Induces Apoptosis in Hepatocellular Carcinoma Cells by Inhibiting the Src/mTOR/STAT3 Signaling Pathway. Int J Mol Sci 2021;22:10509. [PMID: 34638852 DOI: 10.3390/ijms221910509] [Reference Citation Analysis]
67 Chen H, Jia W. Progress in hepatectomy for hepatocellular carcinoma and peri-operation management. Genes Dis 2020;7:320-7. [PMID: 32884986 DOI: 10.1016/j.gendis.2020.02.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
68 Jühling F, Hamdane N, Crouchet E, Li S, El Saghire H, Mukherji A, Fujiwara N, Oudot MA, Thumann C, Saviano A, Roca Suarez AA, Goto K, Masia R, Sojoodi M, Arora G, Aikata H, Ono A, Tabrizian P, Schwartz M, Polyak SJ, Davidson I, Schmidl C, Bock C, Schuster C, Chayama K, Pessaux P, Tanabe KK, Hoshida Y, Zeisel MB, Duong FH, Fuchs BC, Baumert TF. Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. Gut 2021;70:157-69. [PMID: 32217639 DOI: 10.1136/gutjnl-2019-318918] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 31.0] [Reference Citation Analysis]
69 Morishita A, Oura K, Tadokoro T, Fujita K, Tani J, Masaki T. MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review. Cancers (Basel) 2021;13:514. [PMID: 33572780 DOI: 10.3390/cancers13030514] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
70 Zou J, Li S, Wang Q, Mei J, Lu L, Lin W, Wen Y, Li Y, Wei W, Guo R. Surgical strategies for hepatocellular carcinoma located in the left lateral lobe: A propensity score-matched and prognostic nomogram study. Cancer Med 2021;10:3274-87. [PMID: 33932132 DOI: 10.1002/cam4.3894] [Reference Citation Analysis]
71 Czauderna C, Schmidtmann I, Koch S, Pilz L, Heinrich S, Otto G, Mittler J, Lang H, Kloeckner R, Düber C, Sprinzl MF, Worns MA, Galle PR, Marquardt JU, Weinmann A. High pretreatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma. United European Gastroenterol J 2021. [PMID: 33709539 DOI: 10.1177/2050640620972611] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
72 Butterworth J, Gregoire D, Peter M, Roca Suarez AA, Desandré G, Simonin Y, Virzì A, Zine El Aabidine A, Guivarch M, Andrau JC, Bertrand E, Assenat E, Lupberger J, Hibner U. GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication. Pathogens 2021;11:46. [PMID: 35055994 DOI: 10.3390/pathogens11010046] [Reference Citation Analysis]
73 Calvaruso V, Bruix J. Towards personalized screening for hepatocellular carcinoma: Still not there. J Hepatol. 2020;73:1319-1321. [PMID: 32771323 DOI: 10.1016/j.jhep.2020.06.032] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
74 Lal LS, Aly A, Le LB, Peckous S, Seal B, Teitelbaum A. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study. Cancer Rep (Hoboken) 2021;:e1504. [PMID: 34494389 DOI: 10.1002/cnr2.1504] [Reference Citation Analysis]
75 Kubota N, Fujiwara N, Hoshida Y. Clinical and Molecular Prediction of Hepatocellular Carcinoma Risk. J Clin Med 2020;9:E3843. [PMID: 33256232 DOI: 10.3390/jcm9123843] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rattan P, Minacapelli CD, Rustgi V. The Microbiome and Hepatocellular Carcinoma. Liver Transpl. 2020;26:1316-1327. [PMID: 32564483 DOI: 10.1002/lt.25828] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
77 Ortega JF, Heidor R, Auriemo AP, Affonso JM, D'Amico T, Herz C, de Conti A, Ract J, Gioieli LA, Purgatto E, Lamy E, Pogribny I, Moreno FS. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. Carcinogenesis 2021:bgab039. [PMID: 33999989 DOI: 10.1093/carcin/bgab039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 El Fayoumie M, Abdelhady M, Gawish A, Hantour U, Abdelkhaleek I, Abdelraheem M, Alsawak A, Alwassief A, Elbahrawy A. Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents. Gastrointest Tumors 2020;7:50-60. [PMID: 32399465 DOI: 10.1159/000505326] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
79 Martínez-Chantar ML, Avila MA, Lu SC. Hepatocellular Carcinoma: Updates in Pathogenesis, Detection and Treatment. Cancers (Basel) 2020;12:E2729. [PMID: 32977536 DOI: 10.3390/cancers12102729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
80 de Castro T, Jochheim LS, Bathon M, Welland S, Scheiner B, Shmanko K, Roessler D, Khaled NB, Jeschke M, Ludwig JM, Marquardt JU, Weinmann A, Pinter M, Lange CM, Vogel A, Saborowski A. Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience. Ther Adv Med Oncol 2022;14:175883592210802. [DOI: 10.1177/17588359221080298] [Reference Citation Analysis]
81 Gil-Gómez A, Rojas Á, Liu CH, Gallego-Duran R, Muñoz-Hernandez R, Fassina G, Pontisso P, Ampuero J, Romero-Gómez M. Combination of squamous cell carcinoma antigen immunocomplex and alpha-fetoprotein in mid- and long-term prediction of hepatocellular carcinoma among cirrhotic patients. World J Gastroenterol 2021; 27(48): 8343-8356 [DOI: 10.3748/wjg.v27.i48.8343] [Reference Citation Analysis]
82 Li S, Gao D, Jiang Y. Function, Detection and Alteration of Acylcarnitine Metabolism in Hepatocellular Carcinoma. Metabolites 2019;9:E36. [PMID: 30795537 DOI: 10.3390/metabo9020036] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
83 Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World J Gastrointest Oncol 2022; 14(1): 253-264 [DOI: 10.4251/wjgo.v14.i1.253] [Reference Citation Analysis]
84 Tsilimigras DI, Hyer JM, Diaz A, Bagante F, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Synergistic Impact of Alpha-Fetoprotein and Tumor Burden on Long-Term Outcomes Following Curative-Intent Resection of Hepatocellular Carcinoma. Cancers (Basel) 2021;13:747. [PMID: 33670174 DOI: 10.3390/cancers13040747] [Reference Citation Analysis]
85 He L, Zhang Y, Chen J, Liu G, Zhu J, Li X, Li D, Yang Y, Lee CS, Shi J, Yin C, Lai P, Wang L, Fang C. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma. J Mater Chem B 2021;9:8779-92. [PMID: 34635903 DOI: 10.1039/d1tb01729b] [Reference Citation Analysis]
86 Benesch MGK, MacIntyre ITK, McMullen TPW, Brindley DN. Coming of Age for Autotaxin and Lysophosphatidate Signaling: Clinical Applications for Preventing, Detecting and Targeting Tumor-Promoting Inflammation. Cancers (Basel) 2018;10:E73. [PMID: 29543710 DOI: 10.3390/cancers10030073] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 10.3] [Reference Citation Analysis]
87 Yi PS, Hu CJ, Li CH, Yu F. Clinical value of artificial intelligence in hepatocellular carcinoma: Current status and prospect. Artif Intell Gastroenterol 2021; 2(2): 42-55 [DOI: 10.35712/aig.v2.i2.42] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
88 Roderburg C, Özdirik B, Wree A, Demir M, Tacke F. Systemic treatment of hepatocellular carcinoma: from sorafenib to combination therapies. Hepat Oncol 2020;7:HEP20. [PMID: 32647565 DOI: 10.2217/hep-2020-0004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
89 Sai WL, Yao M, Shen SJ, Zheng WJ, Sun JY, Wu MN, Wang L, Yao DF. Dynamic expression of hepatic GP73 mRNA and protein and circulating GP73 during hepatocytes malignant transformation. Hepatobiliary Pancreat Dis Int 2020;19:449-54. [PMID: 32171652 DOI: 10.1016/j.hbpd.2020.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Du X, Zhang Y. Integrated Analysis of Immunity- and Ferroptosis-Related Biomarker Signatures to Improve the Prognosis Prediction of Hepatocellular Carcinoma. Front Genet 2020;11:614888. [PMID: 33391356 DOI: 10.3389/fgene.2020.614888] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
91 Feng Z, Zhao H, Jiang Y, He Z, Sun X, Rong P, Wang W. Sarcopenia associates with increased risk of hepatocellular carcinoma among male patients with cirrhosis. Clinical Nutrition 2020;39:3132-9. [DOI: 10.1016/j.clnu.2020.01.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
92 Chun HS, Park S, Lee M, Cho Y, Kim HS, Choe AR, Kim HY, Yoo K, Kim TH. Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Cancers (Basel) 2021;13:3424. [PMID: 34298640 DOI: 10.3390/cancers13143424] [Reference Citation Analysis]
93 Wang Y, Yang Y, Zhao Z, Sun H, Luo D, Huttad L, Zhang B, Han B. A new nomogram model for prognosis of hepatocellular carcinoma based on novel gene signature that regulates cross-talk between immune and tumor cells. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09465-9] [Reference Citation Analysis]
94 Athuluri-Divakar SK, Hoshida Y. Generic chemoprevention of hepatocellular carcinoma. Ann N Y Acad Sci 2019;1440:23-35. [PMID: 30221358 DOI: 10.1111/nyas.13971] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
95 Mehta KJ, Sharp PA. Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells. Sci Rep 2020;10:21926. [PMID: 33318518 DOI: 10.1038/s41598-020-78348-5] [Reference Citation Analysis]
96 Zhou Y, Li Y, Wang N, Li X, Zheng J, Ge L. UPF1 inhibits the hepatocellular carcinoma progression by targeting long non-coding RNA UCA1. Sci Rep 2019;9:6652. [PMID: 31040354 DOI: 10.1038/s41598-019-43148-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
97 George J, Tsuchishima M, Tsutsumi M. Metabolism of N-nitrosodimethylamine, methylation of macromolecules, and development of hepatic fibrosis in rodent models. J Mol Med (Berl) 2020;98:1203-13. [PMID: 32666246 DOI: 10.1007/s00109-020-01950-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
98 Zhou Y, Liu L, Liu Y, Zhou P, Yan Q, Yu H, Chen X, Zhu F. Implication of human endogenous retrovirus W family envelope in hepatocellular carcinoma promotes MEK/ERK-mediated metastatic invasiveness and doxorubicin resistance. Cell Death Discov 2021;7:177. [PMID: 34238921 DOI: 10.1038/s41420-021-00562-5] [Reference Citation Analysis]
99 Mohr R, Özdirik B, Lambrecht J, Demir M, Eschrich J, Geisler L, Hellberg T, Loosen SH, Luedde T, Tacke F, Hammerich L, Roderburg C. From Liver Cirrhosis to Cancer: The Role of Micro-RNAs in Hepatocarcinogenesis. Int J Mol Sci 2021;22:1492. [PMID: 33540837 DOI: 10.3390/ijms22031492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Zhao S, Zhang T, Li H, Wang M, Xu K, Zheng D, Du X, Liu L. Comparison of albumin-bilirubin grade versus Child-Pugh score in predicting the outcome of transarterial chemoembolization for hepatocellular carcinoma using time-dependent ROC. Ann Transl Med 2020;8:538. [PMID: 32411761 DOI: 10.21037/atm.2020.02.124] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
101 Ali ES, Rychkov GY, Barritt GJ. Targeting Ca2+ Signaling in the Initiation, Promotion and Progression of Hepatocellular Carcinoma. Cancers (Basel) 2020;12:E2755. [PMID: 32987945 DOI: 10.3390/cancers12102755] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
102 Özdirik B, Jost-Brinkmann F, Savic LJ, Mohr R, Tacke F, Ploner CJ, Roderburg C, Müller T. Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review. Medicine (Baltimore) 2021;100:e26377. [PMID: 34128898 DOI: 10.1097/MD.0000000000026377] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Xia L, Wang S, Zhang H, Yang Y, Wei J, Shi Y, Zou C, Liu J, Luo M, Huang A, Wang D. The HBx and HBc of hepatitis B virus can influence Id1 and Id3 by reducing their transcription and stability. Virus Res 2020;284:197973. [PMID: 32305567 DOI: 10.1016/j.virusres.2020.197973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Qi Y, Fan L, Ran D, Xu J, Wang Y, Wu J, Zhang Z. Main Risk Factors of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma. J Oncol 2021;2021:7764817. [PMID: 34691178 DOI: 10.1155/2021/7764817] [Reference Citation Analysis]
105 Chen VC, Lee MJ, Yang YH, Lu ML, Chiu WC, Dewey ME. Selective serotonin reuptake inhibitors use and hepatocellular carcinoma in patients with alcohol use disorder. Drug Alcohol Depend 2021;219:108495. [PMID: 33429293 DOI: 10.1016/j.drugalcdep.2020.108495] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
106 Pomej K, Scheiner B, Park D, Bauer D, Balcar L, Meischl T, Mandorfer M, Reiberger T, Müller C, Trauner M, Pinter M. Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. Cancers (Basel) 2020;12:E2961. [PMID: 33066190 DOI: 10.3390/cancers12102961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
107 Yoon JH, Lee JM, Lee DH, Joo I, Jeon JH, Ahn SJ, Kim ST, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH. A Comparison of Biannual Two-Phase Low-Dose Liver CT and US for HCC Surveillance in a Group at High Risk of HCC Development. Liver Cancer 2020;9:503-17. [PMID: 33083277 DOI: 10.1159/000506834] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
108 Eissa M, Awad S, Barakat S, Saleh A, Rozaik S. Serum Golgi protein 73 as a sensitive biomarker for early detection of hepatocellular carcinoma among Egyptian patients with hepatitis C virus-related cirrhosis. Med J Armed Forces India 2021;77:331-6. [PMID: 34305287 DOI: 10.1016/j.mjafi.2020.11.013] [Reference Citation Analysis]
109 Vilfranc CL, Che LX, Patra KC, Niu L, Olowokure O, Wang J, Shah SA, Du CY. BIR repeat-containing ubiquitin conjugating enzyme (BRUCE) regulation of β-catenin signaling in the progression of drug-induced hepatic fibrosis and carcinogenesis. World J Hepatol 2021; 13(3): 343-361 [PMID: 33815677 DOI: 10.4254/wjh.v13.i3.343] [Reference Citation Analysis]
110 George J, Tsuchishima M, Tsutsumi M. Molecular mechanisms in the pathogenesis of N-nitrosodimethylamine induced hepatic fibrosis. Cell Death Dis 2019;10:18. [PMID: 30622238 DOI: 10.1038/s41419-018-1272-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
111 Tateishi R, Fujiwara N. Precision Locoregional Therapies for Hepatocellular Carcinoma: Percutaneous Ablation and Radiotherapy. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 195-224. [DOI: 10.1007/978-3-030-21540-8_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
112 de Conti A, Tryndyak V, Heidor R, Jimenez L, Moreno FS, Beland FA, Rusyn I, Pogribny IP. Butyrate-containing structured lipids inhibit RAC1 and epithelial-to-mesenchymal transition markers: a chemopreventive mechanism against hepatocarcinogenesis. J Nutr Biochem 2020;86:108496. [PMID: 32920087 DOI: 10.1016/j.jnutbio.2020.108496] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
113 Chong H, Zhou P, Yang C, Zeng M. An excellent nomogram predicts microvascular invasion that cannot independently stratify outcomes of small hepatocellular carcinoma. Ann Transl Med 2021;9:757. [PMID: 34268370 DOI: 10.21037/atm-20-7952] [Reference Citation Analysis]
114 Liu Z, Liu Y, Zhang W, Hong Y, Meng J, Wang J, Zheng S, Xu X. Deep learning for prediction of hepatocellular carcinoma recurrence after resection or liver transplantation: a discovery and validation study. Hepatol Int. [DOI: 10.1007/s12072-022-10321-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
115 Zhao W, Bai B, Hong Z, Zhang X, Zhou B. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells. ACS Omega 2020;5:24838-47. [PMID: 33015502 DOI: 10.1021/acsomega.0c03527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
116 Zhou X, Huang JM, Li TM, Liu JQ, Wei ZL, Lan CL, Zhu GZ, Liao XW, Ye XP, Peng T. Clinical Significance and Potential Mechanisms of ATP Binding Cassette Subfamily C Genes in Hepatocellular Carcinoma. Front Genet 2022;13:805961. [PMID: 35342392 DOI: 10.3389/fgene.2022.805961] [Reference Citation Analysis]
117 Li Z, Li Y, Li X, Zhang L, Zhao N, Du H, Zhou B, Ye Y. Statins on hepatocellular carcinoma risk in hepatitis B or C patients protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11950. [PMID: 30142817 DOI: 10.1097/MD.0000000000011950] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
118 Wu J, Ren X, Wang N, Zhou R, Chen M, Cai Y, Lin S, Zhang H, Xie X, Dang C, Zhang S, Zhou Z. A Mutation-Related Long Noncoding RNA Signature of Genome Instability Predicts Immune Infiltration and Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:779554. [PMID: 34880908 DOI: 10.3389/fgene.2021.779554] [Reference Citation Analysis]
119 Lv J, Liu J, Xiao M, Xu H, Xu C, Zhang X, Tang L, Jiang F, Zhou Y, Zhang Z, Qu L, Lu C. ARP3 promotes tumor metastasis and predicts a poor prognosis in hepatocellular carcinoma. Pathol Res Pract 2018;214:1356-61. [PMID: 30049513 DOI: 10.1016/j.prp.2018.05.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
120 Stepanova M, Younossi Z. Reply. Clin Gastroenterol Hepatol 2019;17:2383-4. [PMID: 31543239 DOI: 10.1016/j.cgh.2019.04.055] [Reference Citation Analysis]
121 Thanapirom K, Caon E, Papatheodoridi M, Frenguelli L, Al-Akkad W, Zhenzhen Z, Vilia MG, Pinzani M, Mazza G, Rombouts K. Optimization and Validation of a Novel Three-Dimensional Co-Culture System in Decellularized Human Liver Scaffold for the Study of Liver Fibrosis and Cancer. Cancers (Basel) 2021;13:4936. [PMID: 34638417 DOI: 10.3390/cancers13194936] [Reference Citation Analysis]
122 Ong JR, Bamodu OA, Khang NV, Lin YK, Yeh CT, Lee WH, Cherng YG. SUMO-Activating Enzyme Subunit 1 (SAE1) Is a Promising Diagnostic Cancer Metabolism Biomarker of Hepatocellular Carcinoma. Cells 2021;10:178. [PMID: 33477333 DOI: 10.3390/cells10010178] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
123 Shokoohian B, Negahdari B, Aboulkheyr Es H, Abedi-Valugerdi M, Baghaei K, Agarwal T, Maiti TK, Hassan M, Najimi M, Vosough M. Advanced therapeutic modalities in hepatocellular carcinoma: Novel insights. J Cell Mol Med 2021;25:8602-14. [PMID: 34423899 DOI: 10.1111/jcmm.16875] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
124 Zhang H, Li JC, Luo H, Zhao L, Zhang ZD, Shen XF. Pseudolaric acid B exhibits anti-cancer activity on human hepatocellular carcinoma through inhibition of multiple carcinogenic signaling pathways. Phytomedicine 2019;59:152759. [PMID: 31004883 DOI: 10.1016/j.phymed.2018.11.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
125 Quintavalle C, Meyer-Schaller N, Roessler S, Calabrese D, Marone R, Riedl T, Picco-Rey S, Panagiotou OA, Uzun S, Piscuoglio S, Boldanova T, Bian CB, Semela D, Jochum W, Cathomas G, Mertz KD, Diebold J, Mazzucchelli L, Koelzer VH, Weber A, Decaens T, Terracciano LM, Heikenwalder M, Hoshida Y, Andersen JB, Thorgeirsson SS, Matter MS. miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatol Commun 2022. [PMID: 35132819 DOI: 10.1002/hep4.1894] [Reference Citation Analysis]
126 Ganne-carrié N, Chaffaut C, Bourcier V, Archambeaud I, Perarnau J, Oberti F, Roulot D, Moreno C, Louvet A, Dao T, Moirand R, Goria O, Nguyen-khac E, Carbonell N, Antonini T, Pol S, de Ledinghen V, Ozenne V, Henrion J, Péron J, Tran A, Perlemuter G, Amiot X, Zarski J, Beaugrand M, Chevret S. Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis. Journal of Hepatology 2018;69:1274-83. [DOI: 10.1016/j.jhep.2018.07.022] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
127 Hoter A, Rizk S, Naim HY. Heat Shock Protein 60 in Hepatocellular Carcinoma: Insights and Perspectives. Front Mol Biosci 2020;7:60. [PMID: 32351972 DOI: 10.3389/fmolb.2020.00060] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
128 Chapman WC, Korenblat KM, Fowler KJ, Saad N, Khan AS, Subramanian V, Doyle MBM, Dageforde LA, Tan B, Grierson P, Lin Y, Xu M, Brunt EM. Hepatocellular carcinoma: Where are we in 2018? Curr Probl Surg 2018;55:450-503. [PMID: 30526875 DOI: 10.1067/j.cpsurg.2018.10.002] [Reference Citation Analysis]
129 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
130 Sun Q, Zhang Z, Lu Y, Liu Q, Xu X, Xu J, Liu Y, Yu H, Yu D, Sun B. Loss of Xanthine Oxidoreductase Potentiates Propagation of Hepatocellular Carcinoma Stem Cells. Hepatology 2020;71:2033-49. [PMID: 31578733 DOI: 10.1002/hep.30978] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
131 Banas B, Kolodziejczyk P, Czerw A, Banas T, Kotwas A, Richter P. A Retrospective, Single-Centre Study on the Learning Curve for Liver Tumor Open Resection in Patients with Hepatocellular Cancers and Intrahepatic Cholagangiocarcinomas. Int J Environ Res Public Health 2022;19:4872. [PMID: 35457739 DOI: 10.3390/ijerph19084872] [Reference Citation Analysis]
132 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
133 Bonilla CM, McGrath NA, Fu J, Xie C. Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus. Hepatoma Res. 2020;6. [PMID: 33134550 DOI: 10.20517/2394-5079.2020.58] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
134 Agioutantis PC, Loutrari H, Kolisis FN. Computational Analysis of Transcriptomic and Proteomic Data for Deciphering Molecular Heterogeneity and Drug Responsiveness in Model Human Hepatocellular Carcinoma Cell Lines. Genes (Basel) 2020;11:E623. [PMID: 32517019 DOI: 10.3390/genes11060623] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
135 Pan Q, Wang L, Liu Y, Li M, Zhang Y, Peng W, Deng T, Peng ML, Jiang JQ, Tang J, Wang J, Duan HX, Fan SS. Knockdown of POLQ interferes the development and progression of hepatocellular carcinoma through regulating cell proliferation, apoptosis and migration. Cancer Cell Int 2021;21:482. [PMID: 34517891 DOI: 10.1186/s12935-021-02178-2] [Reference Citation Analysis]
136 Yip SH, Fujiwara N, Burke J, Shetler A, Peralta C, Qian T, Hoshida H, Zhu S, Hoshida Y. MPIC: Molecular Prognostic Indicators in Cirrhosis Database for Clinical Context-Specific in Silico Prognostic Biomarker Validation. Front Genet 2019;10:830. [PMID: 31620162 DOI: 10.3389/fgene.2019.00830] [Reference Citation Analysis]
137 Zhang X, Jiang D, Yang S, Sun Y, Liu Y, Shi J, Hu C, Pan J, Liu T, Jin B, Yang K. BAP31 Promotes Tumor Cell Proliferation by Stabilizing SERPINE2 in Hepatocellular Carcinoma. Front Cell Dev Biol 2020;8:607906. [PMID: 33363167 DOI: 10.3389/fcell.2020.607906] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
138 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Reference Citation Analysis]
139 Innes H, Jepsen P, McDonald S, Dillon J, Hamill V, Yeung A, Benselin J, Went A, Fraser A, Bathgate A, Ansari MA, Barclay ST, Goldberg D, Hayes PC, Johnson P, Barnes E, Irving W, Hutchinson S, Guha IN. Performance of models to predict hepatocellular carcinoma risk among UK patients with cirrhosis and cured HCV infection. JHEP Rep 2021;3:100384. [PMID: 34805817 DOI: 10.1016/j.jhepr.2021.100384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Fujiwara N, Hoshida Y. Viral Exposure Signature Associated with Liver Cancer Risk. Trends Mol Med 2020;26:711-3. [PMID: 32654969 DOI: 10.1016/j.molmed.2020.06.008] [Reference Citation Analysis]
141 Singal AG, Hoshida Y, Pinato DJ, Marrero J, Nault JC, Paradis V, Tayob N, Sherman M, Lim YS, Feng Z, Lok AS, Rinaudo JA, Srivastava S, Llovet JM, Villanueva A. International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology 2021;160:2572-84. [PMID: 33705745 DOI: 10.1053/j.gastro.2021.01.233] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
142 Xi ZF, Jeong S, Wang CC, Li HJ, Guo H, Cai J, Li JX, Kong XN, Tong Y, Xia Q. Expression of IL-26 predicts prognosis of patients with hepatocellular carcinoma after surgical resection. Hepatobiliary Pancreat Dis Int 2019;18:242-8. [PMID: 30956053 DOI: 10.1016/j.hbpd.2019.03.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
143 Oh KK, Adnan M, Cho DH. Network pharmacology approach to bioactive chemical compounds identified from Lespedeza bicolor lignum methanol extract by GC–MS for amelioration of hepatitis. Gene Reports 2020;21:100851. [DOI: 10.1016/j.genrep.2020.100851] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
144 Al-Azzawi Y, Rouanet E, Hendrix RJ, Spaho L, Malik H, Devuni D, Szabo G, Barnard G. Segmental Distribution of Hepatocellular Carcinoma Correlates with Microvascular Invasion in Liver Explants Undergoing Transplantation. J Cancer Epidemiol 2019;2019:8534372. [PMID: 31186641 DOI: 10.1155/2019/8534372] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
145 Yang Y, Xin Y, Ye F, Liu N, Zhang X, Wang Y, Li X, Fan Q, Zhou X, Chen Y. Early recurrence after radiofrequency ablation for hepatocellular carcinoma: a multicenter retrospective study on definition, patterns and risk factors. Int J Hyperthermia 2021;38:437-46. [PMID: 33724137 DOI: 10.1080/02656736.2020.1849828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Innes H, McDonald SA, Hamill V, Yeung A, Dillon JF, Hayes PC, Went A, Fraser A, Bathgate A, Barclay ST, Janjua N, Goldberg DJ, Hutchinson SJ. Declining incidence of hepatitis C related hepatocellular carcinoma in the era of interferon-free therapies: a population-based cohort study. Liver Int 2021. [PMID: 34951109 DOI: 10.1111/liv.15143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
147 Badolati N, Masselli R, Sommella E, Sagliocchi S, Di Minno A, Salviati E, Campiglia P, Dentice M, Tenore GC, Stornaiuolo M, Novellino E. The Hepatoprotective Effect of Taurisolo, a Nutraceutical Enriched in Resveratrol and Polyphenols, Involves Activation of Mitochondrial Metabolism in Mice Liver. Antioxidants (Basel) 2020;9:E410. [PMID: 32403305 DOI: 10.3390/antiox9050410] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
148 Meng F, Liu J, Lu T, Zang L, Wang J, He Q, Zhou A. SNHG1 knockdown upregulates miR-376a and downregulates FOXK1/Snail axis to prevent tumor growth and metastasis in HCC. Mol Ther Oncolytics 2021;21:264-77. [PMID: 34095464 DOI: 10.1016/j.omto.2021.02.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
149 Du Y, Liu D, Du Y. Recent advances in hepatocellular carcinoma therapeutic strategies and imaging-guided treatment. J Drug Target 2021;:1-15. [PMID: 34727794 DOI: 10.1080/1061186X.2021.1999963] [Reference Citation Analysis]
150 Araujo OC, de Paula VS, do Ó KM, Villela-Nogueira CA, Araujo NM. Association of Polymorphisms in the Glutathione S-Transferase Theta-1 Gene with Cirrhosis and Hepatocellular Carcinoma in Brazilian Patients with Chronic Hepatitis C. Vaccines (Basel) 2021;9:831. [PMID: 34451956 DOI: 10.3390/vaccines9080831] [Reference Citation Analysis]
151 Raja A, Haq F. Molecular classification of hepatocellular carcinoma: prognostic importance and clinical applications. J Cancer Res Clin Oncol 2021. [PMID: 34623518 DOI: 10.1007/s00432-021-03826-w] [Reference Citation Analysis]
152 Wang W, Mu Z, Zhu G, Wang T, Lai S, Guo Y, Yin X, Wen L, Chen D. A Nomogram for Predicting Portal Hypertensive Gastropathy in Patients With Liver Cirrhosis: A Retrospective Analysis. Front Med 2022;9:834159. [DOI: 10.3389/fmed.2022.834159] [Reference Citation Analysis]
153 Yang T, Chen Y, Xu J, Li J, Liu H, Liu N. Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis. BMC Complement Med Ther 2022;22:21. [PMID: 35078445 DOI: 10.1186/s12906-021-03487-9] [Reference Citation Analysis]
154 Crouchet E, Bandiera S, Fujiwara N, Li S, El Saghire H, Fernández-Vaquero M, Riedl T, Sun X, Hirschfield H, Jühling F, Zhu S, Roehlen N, Ponsolles C, Heydmann L, Saviano A, Qian T, Venkatesh A, Lupberger J, Verrier ER, Sojoodi M, Oudot MA, Duong FHT, Masia R, Wei L, Thumann C, Durand SC, González-Motos V, Heide D, Hetzer J, Nakagawa S, Ono A, Song WM, Higashi T, Sanchez R, Kim RS, Bian CB, Kiani K, Croonenborghs T, Subramanian A, Chung RT, Straub BK, Schuppan D, Ankavay M, Cocquerel L, Schaeffer E, Goossens N, Koh AP, Mahajan M, Nair VD, Gunasekaran G, Schwartz ME, Bardeesy N, Shalek AK, Rozenblatt-Rosen O, Regev A, Felli E, Pessaux P, Tanabe KK, Heikenwälder M, Schuster C, Pochet N, Zeisel MB, Fuchs BC, Hoshida Y, Baumert TF. A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. Nat Commun 2021;12:5525. [PMID: 34535664 DOI: 10.1038/s41467-021-25468-9] [Reference Citation Analysis]
155 Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M. Animal Models of Hepatocellular Carcinoma Prevention. Cancers (Basel) 2019;11:E1792. [PMID: 31739536 DOI: 10.3390/cancers11111792] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
156 Setiawan VW, Rosen HR. Stratification of Residual Risk of HCC Following HCV Clearance With Direct-Acting Antivirals in Patients With Advanced Fibrosis and Cirrhosis. Hepatology 2020;72:1897-9. [PMID: 33205438 DOI: 10.1002/hep.31639] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
157 Teal L, Yorio J. Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma. Case Rep Oncol Med 2021;2021:8870334. [PMID: 33859852 DOI: 10.1155/2021/8870334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Chen L, Yi C, Li W, Tseng Y, Zhang J, Liu J. Inhibition of SPATS2 Suppresses Proliferation and Invasion of Hepatocellular Carcinoma Cells through TRIM44-STAT3 Signaling Pathway. J Cancer 2021;12:89-98. [PMID: 33391405 DOI: 10.7150/jca.47526] [Reference Citation Analysis]
159 Liu PH, Hsu CY, Su CW, Huang YH, Hou MC, Rich NE, Fujiwara N, Hoshida Y, Singal AG, Huo TI. Thrombocytosis is associated with worse survival in patients with hepatocellular carcinoma. Liver Int 2020;40:2522-34. [PMID: 32511831 DOI: 10.1111/liv.14560] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
160 Marschner CA, Zhang L, Schwarze V, Völckers W, Froelich MF, von Münchhausen N, Schnitzer ML, Geyer T, Fabritius MP, Rübenthaler J, Clevert DA. The diagnostic value of contrast-enhanced ultrasound (CEUS) for assessing hepatocellular carcinoma compared to histopathology; a retrospective single-center analysis of 119 patients1. Clin Hemorheol Microcirc 2020;76:453-8. [PMID: 33216017 DOI: 10.3233/CH-209221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
161 Ren J, Tong YM, Cui RX, Wang Z, Li QL, Liu W, Qu K, Zhang JY, Liu C, Wan Y. Comparison of survival between adolescent and young adult vs older patients with hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(12): 1394-1406 [PMID: 33362910 DOI: 10.4251/wjgo.v12.i12.1394] [Reference Citation Analysis]
162 Jian J, Nie Y, Huang C, Wan S, Zhu X. A scoring model predicting overall survival for hepatocellular carcinoma patients who receive surgery and chemotherapy. Indian J Surg. [DOI: 10.1007/s12262-021-03224-z] [Reference Citation Analysis]
163 Zuo X, Chen Z, Cai J, Gao W, Zhang Y, Han G, Pu L, Wu Z, You W, Qin J, Dai X, Shen H, Wu J, Wang X. 5-Hydroxytryptamine Receptor 1D Aggravates Hepatocellular Carcinoma Progression Through FoxO6 in AKT-Dependent and Independent Manners. Hepatology 2019;69:2031-47. [PMID: 30561038 DOI: 10.1002/hep.30430] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
164 Dai Q, Zhang C, Yuan Z, Sun Q, Jiang Y. Current discovery strategies for hepatocellular carcinoma therapeutics. Expert Opinion on Drug Discovery 2020;15:243-58. [DOI: 10.1080/17460441.2020.1696769] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
165 Guan R, Sun B, Wang Z, Zhou C, Yang Z, Gan W, Huang J, Liu G, Zhou J, Fan J, Yi Y, Qiu S. Antiviral therapy improves postoperative survival of patients with HBV-related hepatocellular carcinoma. The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.01.008] [Reference Citation Analysis]
166 Pu Z, Ge F, Wang Y, Jiang Z, Zhu S, Qin S, Dai Q, Liu H, Hua H. Ginsenoside-Rg3 inhibits the proliferation and invasion of hepatoma carcinoma cells via regulating long non-coding RNA HOX antisense intergenic. Bioengineered 2021;12:2398-409. [PMID: 34130594 DOI: 10.1080/21655979.2021.1932211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
167 Son Y, Shin NR, Kim SH, Park SC, Lee HJ. Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells. Int J Mol Sci 2021;22:5330. [PMID: 34069373 DOI: 10.3390/ijms22105330] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
168 Ganne-Carrié N, Nahon P. Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 2019;70:284-93. [PMID: 30658729 DOI: 10.1016/j.jhep.2018.10.008] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 32.0] [Reference Citation Analysis]
169 Erstad DJ, Razavi AA, Li S, Tanabe KK, Fuchs BC. Prevention Strategies for Hepatocellular Carcinoma. In: Hoshida Y, editor. Hepatocellular Carcinoma. Cham: Springer International Publishing; 2019. pp. 255-89. [DOI: 10.1007/978-3-030-21540-8_13] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
170 Liu Y, Zhang Y, Du D, Gu X, Zhou S. PCDH17 is regulated by methylation of DNMT3B and affects the malignant biological behavior of HCC through EMT. Experimental Cell Research 2022. [DOI: 10.1016/j.yexcr.2022.113245] [Reference Citation Analysis]
171 Li S, Ghoshal S, Sojoodi M, Arora G, Masia R, Erstad DJ, Lanuti M, Hoshida Y, Baumert TF, Tanabe KK, Fuchs BC. Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. J Gastrointest Surg. 2019;23:101-111. [PMID: 30367397 DOI: 10.1007/s11605-018-4004-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
172 Chen E, Zhou B, Bian S, Ni W, Chen Z. The lncRNA B3GALT5-AS1 Functions as an HCC Suppressor by Regulating the miR-934/UFM1 Axis. J Oncol 2021;2021:1776432. [PMID: 34721576 DOI: 10.1155/2021/1776432] [Reference Citation Analysis]
173 Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Reference Citation Analysis]
174 Imaoka Y, Ohira M, Sato K, Imaoka K, Kuroda S, Tahara H, Kobayashi T, Ide K, Tanaka Y, Ohdan H. Impact of abdominal aortic calcification on clinical outcomes following initial hepatectomy for hepatocellular carcinoma: A retrospective cohort study. Ann Gastroenterol Surg. [DOI: 10.1002/ags3.12508] [Reference Citation Analysis]
175 Wang J, Han K, Zhang C, Chen X, Li Y, Zhu L, Luo T. Identification and validation of ferroptosis-associated gene-based on immune score as prognosis markers for hepatocellular carcinoma patients. J Gastrointest Oncol 2021;12:2345-60. [PMID: 34790397 DOI: 10.21037/jgo-21-237] [Reference Citation Analysis]
176 Hamdane N, Jühling F, Crouchet E, El Saghire H, Thumann C, Oudot MA, Bandiera S, Saviano A, Ponsolles C, Roca Suarez AA, Li S, Fujiwara N, Ono A, Davidson I, Bardeesy N, Schmidl C, Bock C, Schuster C, Lupberger J, Habersetzer F, Doffoël M, Piardi T, Sommacale D, Imamura M, Uchida T, Ohdan H, Aikata H, Chayama K, Boldanova T, Pessaux P, Fuchs BC, Hoshida Y, Zeisel MB, Duong FHT, Baumert TF. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response. Gastroenterology 2019;156:2313-2329.e7. [PMID: 30836093 DOI: 10.1053/j.gastro.2019.02.038] [Cited by in Crossref: 85] [Cited by in F6Publishing: 83] [Article Influence: 28.3] [Reference Citation Analysis]
177 Xie C, Wu H, Pan T, Zheng X, Yang X, Zhang G, Lian Y, Lin J, Peng L. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:8563-87. [PMID: 33714200 DOI: 10.18632/aging.202670] [Reference Citation Analysis]
178 Cagnin M, Biasiolo A, Martini A, Ruvoletto M, Quarta S, Fasolato S, Angeli P, Fassina G, Pontisso P. Serum Squamous Cell Carcinoma Antigen-Immunoglobulin M complex levels predict survival in patients with cirrhosis. Sci Rep 2019;9:20126. [PMID: 31882893 DOI: 10.1038/s41598-019-56633-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
179 Gallon J, Coto-Llerena M, Ercan C, Bianco G, Paradiso V, Nuciforo S, Taha-Melitz S, Meier MA, Boldanova T, Pérez-Del-Pulgar S, Rodríguez-Tajes S, von Flüe M, Soysal SD, Kollmar O, Llovet JM, Villanueva A, Terracciano LM, Heim MH, Ng CKY, Piscuoglio S. Epigenetic priming in chronic liver disease impacts the transcriptional and genetic landscapes of hepatocellular carcinoma. Mol Oncol 2021. [PMID: 34863035 DOI: 10.1002/1878-0261.13154] [Reference Citation Analysis]
180 Hou X, Liu W, Yang X, Shao C, Gao L, Zhang L, Wei L. Extracellular microparticles derived from hepatic progenitor cells deliver a death signal to hepatoma-initiating cells. J Nanobiotechnol 2022;20. [DOI: 10.1186/s12951-022-01280-5] [Reference Citation Analysis]
181 Tsilimigras DI, Hyer JM, Diaz A, Moris D, Abbas A, Dillhoff M, Cloyd JM, Ejaz A, Beane JD, Tsung A, Pawlik TM. Impact of cancer center accreditation on outcomes of patients undergoing resection for hepatocellular carcinoma: A SEER-Medicare analysis. Am J Surg 2021;222:570-6. [PMID: 33485619 DOI: 10.1016/j.amjsurg.2021.01.015] [Reference Citation Analysis]
182 Zayed Mohamed N, Aly HF, Moneim El-Mezayen HA, El-Salamony HE. Effect of co-administration of Bee honey and some chemotherapeutic drugs on dissemination of hepatocellular carcinoma in rats. Toxicol Rep 2019;6:875-88. [PMID: 31516840 DOI: 10.1016/j.toxrep.2019.08.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
183 Yarchoan M, Agarwal P, Villanueva A, Rao S, Dawson LA, Llovet JM, Finn RS, Groopman JD, El-Serag HB, Monga SP, Wang XW, Karin M, Schwartz RE, Tanabe KK, Roberts LR, Gunaratne PH, Tsung A, Brown KA, Lawrence TS, Salem R, Singal AG, Kim AK, Rabiee A, Resar L, Hoshida Y, He AR, Ghoshal K, Ryan PB, Jaffee EM, Guha C, Mishra L, Coleman CN, Ahmed MM. Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. Cancer Res. 2019;79:4326-4330. [PMID: 31481419 DOI: 10.1158/0008-5472.can-19-0803] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 20.0] [Reference Citation Analysis]
184 Su L, Zhang G, Kong X. A Novel Five-Gene Signature for Prognosis Prediction in Hepatocellular Carcinoma. Front Oncol 2021;11:642563. [PMID: 34336648 DOI: 10.3389/fonc.2021.642563] [Reference Citation Analysis]
185 Hastir JF, Delbauve S, Larbanoix L, Germanova D, Goyvaerts C, Allard J, Laurent S, Breckpot K, Beschin A, Guilliams M, Flamand V. Hepatocarcinoma Induces a Tumor Necrosis Factor-Dependent Kupffer Cell Death Pathway That Favors Its Proliferation Upon Partial Hepatectomy. Front Oncol 2020;10:547013. [PMID: 33178579 DOI: 10.3389/fonc.2020.547013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
186 Zhao Z, Zhao Z, Wang J, Zhang H, Xi Z, Xia Q. ABCC6 Knockdown Fuels Cell Proliferation by Regulating PPARα in Hepatocellular Carcinoma. Front Oncol 2022;12:840287. [PMID: 35280774 DOI: 10.3389/fonc.2022.840287] [Reference Citation Analysis]
187 Woo HY, Yoo SY, Heo J. Peretinoin, an Acyclic Retinoid, for the Secondary Prevention of Hepatocellular Carcinoma. Molecules 2021;26:E295. [PMID: 33435572 DOI: 10.3390/molecules26020295] [Reference Citation Analysis]
188 Hamada T, Nowak JA, Milner DA jr. Song M, Ogino S. Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms. J Pathol. 2019;247:615-628. [PMID: 30632609 DOI: 10.1002/path.5236] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 16.0] [Reference Citation Analysis]
189 Fujiwara N, Qian T, Koneru B, Hoshida Y. Omics-derived hepatocellular carcinoma risk biomarkers for precision care of chronic liver diseases. Hepatol Res 2020;50:817-30. [PMID: 32323426 DOI: 10.1111/hepr.13506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
190 Liu LM, Lin P, Yang H, Dang YW, Chen G. Gene profiling of HepG2 cells following nitidine chloride treatment: An investigation with microarray and Connectivity Mapping. Oncol Rep 2019;41:3244-56. [PMID: 30942464 DOI: 10.3892/or.2019.7091] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
191 Zhou W, Fang D, He Y, Wei J. Correlation analysis of tumor mutation burden of hepatocellular carcinoma based on data mining. J Gastrointest Oncol 2021;12:1117-31. [PMID: 34295561 DOI: 10.21037/jgo-21-259] [Reference Citation Analysis]
192 Lee SK, Chung DJ, Cho SH. A Real-World Comparative Study of Microwave and Radiofrequency Ablation in Treatment-Naïve and Recurrent Hepatocellular Carcinoma. J Clin Med 2022;11:302. [PMID: 35053997 DOI: 10.3390/jcm11020302] [Reference Citation Analysis]
193 Lambrecht J, Porsch-Özçürümez M, Best J, Jost-Brinkmann F, Roderburg C, Demir M, Tacke F, Mohr R. The APAC Score: A Novel and Highly Performant Serological Tool for Early Diagnosis of Hepatocellular Carcinoma in Patients with Liver Cirrhosis. J Clin Med 2021;10:3392. [PMID: 34362181 DOI: 10.3390/jcm10153392] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
194 Ladju RB, Ulhaq ZS, Soraya GV. Nanotheranostics: A powerful next-generation solution to tackle hepatocellular carcinoma. World J Gastroenterol 2022; 28(2): 176-187 [DOI: 10.3748/wjg.v28.i2.176] [Reference Citation Analysis]
195 Li M, Cui ZG, Zakki SA, Feng Q, Sun L, Feril LB Jr, Inadera H. Aluminum chloride causes 5-fluorouracil resistance in hepatocellular carcinoma HepG2 cells. J Cell Physiol 2019;234:20249-65. [PMID: 30993729 DOI: 10.1002/jcp.28625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
196 Lupberger J, Baumert TF. Virus-Induced Risk of Hepatocellular Carcinoma: Recent Progress and Future Challenges. J Clin Med 2021;11:208. [PMID: 35011949 DOI: 10.3390/jcm11010208] [Reference Citation Analysis]
197 Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity Breeds Strategy: In Silico Untangling of the Molecular Complexity on Course of Autoimmune Liver Disease-to-Hepatocellular Carcinoma Transition Predicts Novel Transcriptional Signatures. Cells 2021;10:1917. [PMID: 34440687 DOI: 10.3390/cells10081917] [Reference Citation Analysis]
198 Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M. MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer. Mol Ther Nucleic Acids 2019;14:239-50. [PMID: 30641476 DOI: 10.1016/j.omtn.2018.11.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
199 Fujiwara N, Singal AG, Hoshida Y. Dose and Duration of Aspirin Use to Reduce Incident Hepatocellular Carcinoma. Hepatology 2019;70:2216-7. [PMID: 31206214 DOI: 10.1002/hep.30813] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
200 Petyaev IM, Dovgalevsky PY, Chalyk NE, Klochkov VA, Kyle NH, Bashmakov YK. Reduction of Liver Span and Parameters of Inflammation in Nonalcoholic Fatty Liver Disease Patients Treated with Lycosome Formulation of Phosphatidylcholine: A Preliminary Report. Int J Chronic Dis 2018;2018:4549614. [PMID: 29805971 DOI: 10.1155/2018/4549614] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Kuznietsova H, Dziubenko N, Hurmach V, Chereschuk I, Motuziuk O, Ogloblya O, Prylutskyy Y. Water-Soluble Pristine C60 Fullerenes Inhibit Liver Fibrotic Alteration and Prevent Liver Cirrhosis in Rats. Oxid Med Cell Longev 2020;2020:8061246. [PMID: 32148657 DOI: 10.1155/2020/8061246] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
202 Fujiwara N, Kobayashi M, Fobar AJ, Hoshida A, Marquez CA, Koneru B, Panda G, Taguri M, Qian T, Raman I, Li QZ, Hoshida H, Sezaki H, Kumada H, Tateishi R, Yokoo T, Yopp AC, Chung RT, Fuchs BC, Baumert TF, Marrero JA, Parikh ND, Zhu S, Singal AG, Hoshida Y. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis. Med (N Y) 2021;2:836-850.e10. [PMID: 34318286 DOI: 10.1016/j.medj.2021.03.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
203 Fernández-Barrena MG, Arechederra M, Colyn L, Berasain C, Avila MA. Epigenetics in hepatocellular carcinoma development and therapy: The tip of the iceberg. JHEP Rep 2020;2:100167. [PMID: 33134907 DOI: 10.1016/j.jhepr.2020.100167] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
204 Lian J, Zou Y, Huang L, Cheng H, Huang K, Zeng J, Chen L. Hepatitis B virus upregulates cellular inhibitor of apoptosis protein 2 expression via the PI3K/AKT/NF-κB signaling pathway in liver cancer. Oncol Lett 2020;19:2043-52. [PMID: 32194701 DOI: 10.3892/ol.2020.11267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
205 Deng H, Shang W, Wang K, Guo K, Liu Y, Tian J, Fang C. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles. J Nanobiotechnology 2022;20:156. [PMID: 35331259 DOI: 10.1186/s12951-022-01378-w] [Reference Citation Analysis]
206 Llorens-Revull M, Costafreda MI, Rico A, Guerrero-Murillo M, Soria ME, Píriz-Ruzo S, Vargas-Accarino E, Gabriel-Medina P, Rodríguez-Frías F, Riveiro-Barciela M, Perales C, Quer J, Sauleda S, Esteban JI, Bes M. Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy. PLoS One 2021;16:e0254243. [PMID: 34242330 DOI: 10.1371/journal.pone.0254243] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
207 Chen Z, Du J, Yang C, Si G, Chen Y. circ-CFH promotes the development of HCC by regulating cell proliferation, apoptosis, migration, invasion, and glycolysis through the miR-377-3p/RNF38 axis. Open Life Sciences 2022;17:248-60. [DOI: 10.1515/biol-2022-0029] [Reference Citation Analysis]
208 Beaufrère A, Calderaro J, Paradis V. Combined hepatocellular-cholangiocarcinoma: An update. J Hepatol 2021;74:1212-24. [PMID: 33545267 DOI: 10.1016/j.jhep.2021.01.035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
209 Tsilimigras DI, Bagante F, Moris D, Merath K, Paredes AZ, Sahara K, Ratti F, Marques HP, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Defining the chance of cure after resection for hepatocellular carcinoma within and beyond the Barcelona Clinic Liver Cancer guidelines: A multi-institutional analysis of 1,010 patients. Surgery 2019;166:967-74. [DOI: 10.1016/j.surg.2019.08.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
210 Woeste MR, Geller AE, Martin RCG 2nd, Polk HC Jr. Optimizing the Combination of Immunotherapy and Trans-Arterial Locoregional Therapy for Stages B and C Hepatocellular Cancer. Ann Surg Oncol 2021;28:1499-510. [PMID: 33393028 DOI: 10.1245/s10434-020-09414-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
211 Liu J, Jiang J, Mo J, Liu D, Cao D, Wang H, He Y, Wang H. Global DNA 5-Hydroxymethylcytosine and 5-Formylcytosine Contents Are Decreased in the Early Stage of Hepatocellular Carcinoma. Hepatology 2019;69:196-208. [PMID: 30070373 DOI: 10.1002/hep.30146] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 15.0] [Reference Citation Analysis]
212 Gui H, Huang Y, Zhao G, Chen L, Cai W, Wang H, Guo Q, Xie Q. External Validation of aMAP Hepatocellular Carcinoma Risk Score in Patients With Chronic Hepatitis B-Related Cirrhosis Receiving ETV or TDF Therapy. Front Med (Lausanne) 2021;8:677920. [PMID: 34422855 DOI: 10.3389/fmed.2021.677920] [Reference Citation Analysis]
213 Sun ZP, Tan ZG, Peng C. Long noncoding RNA LINC01419 promotes hepatocellular carcinoma malignancy by mediating miR-485-5p/LSM4 axis. Kaohsiung J Med Sci 2022. [PMID: 35748489 DOI: 10.1002/kjm2.12566] [Reference Citation Analysis]
214 Wei Y, Yang C, Wei Z, Liao X, He Y, Zhou X, Huang H, Lan C, Han C, Peng T. High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma. IJGM 2022;Volume 15:609-21. [DOI: 10.2147/ijgm.s344858] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
215 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
216 Zhou S, Xu J, Wang D, Wang Y, Meng L, Cao S. Development an Immune-Related MicroRNA Risk Index in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/5224434] [Reference Citation Analysis]
217 Zhang S, Zhang F, Chen Q, Wan C, Xiong J, Xu J. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway. J Exp Clin Cancer Res 2019;38:467. [PMID: 31727171 DOI: 10.1186/s13046-019-1462-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
218 Lee NCW, Carella MA, Papa S, Bubici C. High Expression of Glycolytic Genes in Cirrhosis Correlates With the Risk of Developing Liver Cancer. Front Cell Dev Biol 2018;6:138. [PMID: 30430110 DOI: 10.3389/fcell.2018.00138] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
219 Yan Z, Da Q, Li Z, Lin Q, Yi J, Su Y, Yu G, Ren Q, Liu X, Lin Z, Qu J, Yin W, Liu J. Inhibition of NEK7 Suppressed Hepatocellular Carcinoma Progression by Mediating Cancer Cell Pyroptosis. Front Oncol 2022;12:812655. [PMID: 35223495 DOI: 10.3389/fonc.2022.812655] [Reference Citation Analysis]
220 Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)00326-3. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
221 Roeb E. Nichtalkoholische Steatohepatitis (NASH) und alkoholische Steatohepatitis (ASH). Drug Res (Stuttg) 2021;71:S16-8. [PMID: 34788881 DOI: 10.1055/a-1606-5858] [Reference Citation Analysis]
222 Zhang S, Mo Z, Zhang S, Li X. A Network Pharmacology Approach to Reveal the Underlying Mechanisms of Artemisia annua on the Treatment of Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:8947304. [PMID: 33688369 DOI: 10.1155/2021/8947304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
223 Tsilimigras DI, Mehta R, Paredes AZ, Moris D, Sahara K, Bagante F, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Spolverato G, Umberto C, Pawlik TM. Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria. Ann Surg 2020;272:574-81. [PMID: 32932309 DOI: 10.1097/SLA.0000000000004346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
224 Zhang GC, Liu J, Yu XN, Deng Y, Sun Y, Liu TT, Dong L, Zhu CF, Shen XZ, Zhu JM, Weng SQ, Li Y. Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma. Adv Healthc Mater 2020;9:e2000650. [PMID: 33000919 DOI: 10.1002/adhm.202000650] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
225 Cooper GS. Should We Abandon Current Hepatocellular Carcinoma Screening Practices? Gastroenterology 2018;155:972-4. [DOI: 10.1053/j.gastro.2018.09.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
226 Yang SY, Wang CC, Chen KD, Liu YW, Lin CC, Chuang CH, Tsai YC, Yao CC, Yen YH, Hsiao CC, Hu TH, Tsai MC. Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma. BMC Cancer 2021;21:70. [PMID: 33446127 DOI: 10.1186/s12885-021-07796-7] [Reference Citation Analysis]
227 Yang L, Gu D, Wei J, Yang C, Rao S, Wang W, Chen C, Ding Y, Tian J, Zeng M. A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma. Liver Cancer. 2019;8:373-386. [PMID: 31768346 DOI: 10.1159/000494099] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
228 Romano F, Chiarelli M, Garancini M, Scotti M, Zago M, Cioffi G, De Simone M, Cioffi U. Rethinking the Barcelona clinic liver cancer guidelines: Intermediate stage and Child-Pugh B patients are suitable for surgery? World J Gastroenterol 2021; 27(21): 2784-2794 [PMID: 34135554 DOI: 10.3748/wjg.v27.i21.2784] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
229 Mu D, Qin F, Li B, Zhou Q. Identification of the Sixth Complement Component as Potential Key Genes in Hepatocellular Carcinoma via Bioinformatics Analysis. Biomed Res Int 2020;2020:7042124. [PMID: 33083480 DOI: 10.1155/2020/7042124] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
230 Nahon P, Vo Quang E, Ganne-Carrié N. Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control. J Clin Med 2021;10:353. [PMID: 33477752 DOI: 10.3390/jcm10020353] [Reference Citation Analysis]
231 Zhang Z, Zhang Y, Mo W. The Autophagy Related Gene CHAF1B Is a Relevant Prognostic and Diagnostic Biomarker in Hepatocellular Carcinoma. Front Oncol 2020;10:626175. [PMID: 33575221 DOI: 10.3389/fonc.2020.626175] [Reference Citation Analysis]
232 Barone M, Di Leo A, Sabbà C, Mazzocca A. The perplexity of targeting genetic alterations in hepatocellular carcinoma. Med Oncol 2020;37:67. [PMID: 32699957 DOI: 10.1007/s12032-020-01392-8] [Reference Citation Analysis]
233 Zhao Y, Sun Y, Yang J, Zhu Z, Jia X. WITHDRAWN: Circ_0000517 contributes to hepatocellular carcinoma progression by upregulating ARID4B via sponging miR-328-3p. Cell Signal 2021;:109950. [PMID: 33582185 DOI: 10.1016/j.cellsig.2021.109950] [Reference Citation Analysis]
234 Toh TB, Liu Z, Yu H, Fong ELS. Three-Dimensional Macroporous Sponge for the Culture of Hepatocellular Carcinoma Patient-Derived Xenograft Organoids. SLAS Technol 2021;26:249-54. [PMID: 33775155 DOI: 10.1177/24726303211000685] [Reference Citation Analysis]
235 Lyu Z, Ma M, Xu Y, Wang X, Zhu Y, Ren W, Li T. Expression and prognostic significance of epithelial tissue-specific transcription factor ESE3 in hepatocellular carcinoma. Int J Clin Oncol 2020;25:1334-45. [PMID: 32347431 DOI: 10.1007/s10147-020-01675-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
236 Pagano AP, Sicchieri JMF, Schiavoni IL, Barbeiro D, Manca CS, da Silva BR, Bezerra AE, Pinto LCM, Araújo RC, Teixeira AC, Chiarello PG. Phase angle as a severity indicator for liver diseases. Nutrition 2020;70:110607. [DOI: 10.1016/j.nut.2019.110607] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
237 Chen J, Tang D, Li H, Zhang P. Expression changes of serum LINC00941 and LINC00514 in HBV infection-related liver diseases and their potential application values. J Clin Lab Anal 2021;:e24143. [PMID: 34825738 DOI: 10.1002/jcla.24143] [Reference Citation Analysis]
238 Mohr R, Jost-Brinkmann F, Özdirik B, Lambrecht J, Hammerich L, Loosen SH, Luedde T, Demir M, Tacke F, Roderburg C. Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma. Front Immunol 2021;12:652172. [PMID: 33859646 DOI: 10.3389/fimmu.2021.652172] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
239 Kim JH, Kang SH, Lee M, Youn GS, Kim TS, Jun BG, Kim MY, Kim YD, Cheon GJ, Kim DJ, Baik SK, Choi DH, Suk KT. Serum Myostatin Predicts the Risk of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis: A Multicenter Study. Cancers (Basel) 2020;12:E3347. [PMID: 33198216 DOI: 10.3390/cancers12113347] [Reference Citation Analysis]
240 Ali ES, Rychkov GY, Barritt GJ. Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. Cell Calcium 2019;82:102057. [PMID: 31401389 DOI: 10.1016/j.ceca.2019.102057] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
241 Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Simon TG, Ma Y, Ludvigsson JF, Chong DQ, Giovannucci EL, Fuchs CS, Meyerhardt JA, Corey KE, Chung RT, Zhang X, Chan AT. Association Between Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncol 2018;4:1683-90. [PMID: 30286235 DOI: 10.1001/jamaoncol.2018.4154] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 27.0] [Reference Citation Analysis]
243 Yang MY, Wu F, Fang F, Yang H, Zhang JF, Chen GD, Yang LY. Serum epidermal growth factor-like domain 7 serves as a novel diagnostic marker for early hepatocellular carcinoma. BMC Cancer 2021;21:772. [PMID: 34217251 DOI: 10.1186/s12885-021-08491-3] [Reference Citation Analysis]
244 Ni H, Lu Z, Huang X, Ning S, Liang X, Zhang S, Xiang B. Combining Pre- and Postoperative Lymphocyte–C-Reactive Protein Ratios Can Better Predict Hepatocellular Carcinoma Prognosis After Partial Hepatectomy. JIR 2022;Volume 15:2229-41. [DOI: 10.2147/jir.s359498] [Reference Citation Analysis]
245 Li P, Liu Y, He Q. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation. Drug Des Devel Ther 2020;14:1609-20. [PMID: 32425506 DOI: 10.2147/DDDT.S243383] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol 2019;16:748-66. [PMID: 31666728 DOI: 10.1038/s41575-019-0217-8] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
247 Korean Liver Cancer Association., National Cancer Center. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver 2019;13:227-99. [PMID: 31060120 DOI: 10.5009/gnl19024] [Cited by in Crossref: 90] [Cited by in F6Publishing: 90] [Article Influence: 45.0] [Reference Citation Analysis]
248 Chang T, Hsu N, Chen S, Hsu I, Lee M, Lu S. Non-B, Non-C Hepatocellular Carcinoma in an HBV- and HCV-Endemic Area: A Community-Based Prospective Longitudinal Study. Viruses 2022;14:984. [DOI: 10.3390/v14050984] [Reference Citation Analysis]
249 Yang L, Cao J, Wei J, Deng J, Hou X, Hao E, Du Z, Zou L, Li P. Antiproliferative activity of berberine in HepG2 cells via inducing apoptosis and arresting cell cycle. Food Funct 2021;12:12115-26. [PMID: 34787617 DOI: 10.1039/d1fo02783b] [Reference Citation Analysis]
250 Kong J, Li D, Zhang S, Zhang H, Fu Y, Qian B, Bei C, Tan S, Zhu X. Okadaic acid promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting protein phosphatase 2A. J Cell Biochem 2020. [PMID: 31904141 DOI: 10.1002/jcb.29629] [Reference Citation Analysis]
251 Tsilimigras DI, Moris D, Hyer JM, Bagante F, Sahara K, Moro A, Paredes AZ, Mehta R, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Sasaki K, Rodarte AI, Aucejo FN, Pawlik TM. Hepatocellular carcinoma tumour burden score to stratify prognosis after resection. Br J Surg 2020;107:854-64. [PMID: 32057105 DOI: 10.1002/bjs.11464] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
252 Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69:345-352. [PMID: 29551707 DOI: 10.1016/j.jhep.2018.03.009] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 16.5] [Reference Citation Analysis]
253 Sun F, Liu Y, Gong T, Pan Q, Xiang T, Zhao J, Tang Y, Chen H, Han Y, Song M, Huang Y, Li H, Chen Y, Yang C, Yang J, Wang Q, Li Y, He J, Weng D, Peng R, Xia J. Inhibition of DTYMK significantly restrains the growth of HCC and increases sensitivity to oxaliplatin. Cell Death Dis 2021;12:1093. [PMID: 34795209 DOI: 10.1038/s41419-021-04375-3] [Reference Citation Analysis]
254 Strathearn LS, Stepanov AI, Font-Burgada J. Inflammation in Primary and Metastatic Liver Tumorigenesis-Under the Influence of Alcohol and High-Fat Diets. Nutrients 2020;12:E933. [PMID: 32230953 DOI: 10.3390/nu12040933] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
255 Lu C, Fang S, Weng Q, Lv X, Meng M, Zhu J, Zheng L, Hu Y, Gao Y, Wu X, Mao J, Tang B, Zhao Z, Huang L, Ji J. Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma. Cell Commun Signal 2020;18:97. [PMID: 32576292 DOI: 10.1186/s12964-020-00539-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
256 Jin F, Wang R, Zhu Y, Chen J, Cao W, Wang Y, Wu Y, Song X, Huang Y, Dong J, Ren Z. A novel quinolinylmethyl substituted ethylenediamine compound exerts anti-cancer effects via stimulating the accumulation of reactive oxygen species and NO in hepatocellular carcinoma cells. Eur J Pharmacol 2020;885:173497. [PMID: 32841641 DOI: 10.1016/j.ejphar.2020.173497] [Reference Citation Analysis]
257 Li Y, Zhang Y, Fang Q, Zhang X, Hou P, Wu H, Wang X. Radiomics analysis of [18F]FDG PET/CT for microvascular invasion and prognosis prediction in very-early- and early-stage hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2021;48:2599-614. [PMID: 33416951 DOI: 10.1007/s00259-020-05119-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
258 Ibrahim EA, Moawed FSM, Moustafa EM. Suppression of inflammatory cascades via novel cinnamic acid nanoparticles in acute hepatitis rat model. Arch Biochem Biophys 2020;696:108658. [PMID: 33144082 DOI: 10.1016/j.abb.2020.108658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Ding B, Lou W, Liu J, Li R, Chen J, Fan W. In silico analysis excavates potential biomarkers by constructing miRNA-mRNA networks between non-cirrhotic HCC and cirrhotic HCC. Cancer Cell Int. 2019;19:186. [PMID: 31346321 DOI: 10.1186/s12935-019-0901-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
260 Dai Q, Liu T, Gao Y, Zhou H, Li X, Zhang W. Six genes involved in prognosis of hepatocellular carcinoma identified by Cox hazard regression. BMC Bioinformatics 2021;22:167. [PMID: 33784984 DOI: 10.1186/s12859-021-04095-7] [Reference Citation Analysis]
261 Chen D, Li X, Li H, Wang K, Tian X. Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. J Oncol 2022;2022:5313149. [PMID: 35027925 DOI: 10.1155/2022/5313149] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
262 Mårdh O, Quinten C, Amato-Gauci AJ, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA - descriptive analysis and estimation of 2015 baseline. Infect Dis (Lond) 2020;52:625-37. [PMID: 32644030 DOI: 10.1080/23744235.2020.1766104] [Reference Citation Analysis]
263 You Y, Zhang M, Li K, Zeng Q, Luo L, Long Y, Tan L, He X, Liang P, Xu E, Zheng R. Feasibility of 3D US/CEUS-US/CEUS fusion imaging-based ablation planning in liver tumors: a retrospective study. Abdom Radiol (NY) 2021;46:2865-74. [PMID: 33484284 DOI: 10.1007/s00261-020-02909-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
264 Moon H, Cho K, Shin S, Kim DY, Han KH, Ro SW. High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway. Int J Mol Sci. 2019;20. [PMID: 30700007 DOI: 10.3390/ijms20030581] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]